Related Experiment Video

Updated: Dec 15, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.9K

Mobile Phone Technologies in the Management of Ischemic Heart Disease, Heart Failure, and Hypertension: Systematic

Praveen Indraratna1,2, Daniel Tardo3,4, Jennifer Yu1,2

  • 1Department of Cardiology, Prince of Wales Hospital, Sydney, Australia.

JMIR Mhealth and Uhealth
|July 7, 2020
PubMed

Insights

Mobile phone interventions (MPIs) can help manage cardiovascular diseases (CVD). Studies show MPIs reduce hospitalizations for heart failure and lower blood pressure in hypertension patients.

Area of Science:

  • Cardiology
  • Digital Health
  • Public Health

Background:

  • Cardiovascular disease (CVD) is a leading global cause of mortality.
  • Mobile phones are widespread, offering new avenues for chronic disease management.
  • Smartphone apps, telemonitoring, and SMS are emerging tools for managing conditions like heart failure and hypertension.

Purpose of the Study:

  • To systematically review randomized control trials (RCTs) on mobile phone interventions (MPIs) for chronic CVD management.
  • To assess the impact of MPIs on mortality, hospitalizations, blood pressure (BP), and body mass index (BMI).

Main Methods:

  • A systematic review of seven electronic databases was conducted from January 2000 to June 2019.
  • Twenty-six RCTs involving 6713 patients were identified; 12 were included in a meta-analysis.
  • Meta-analysis used standard techniques with odds ratios for dichotomous variables and a random effect model.

Main Results:

  • Mobile phone interventions (MPIs) significantly reduced hospitalizations in heart failure patients (OR 0.77, P=.03).
  • MPIs were associated with a significant decrease in systolic blood pressure for hypertension patients (mean difference -4.3 mm Hg, P=.02).
  • A total of 26 RCTs with 6713 patients were analyzed.

Conclusions:

  • Mobile phone interventions show promise as a valuable addition to managing chronic cardiovascular diseases.
  • Further research may solidify the role of digital health tools in cardiovascular care.
  • MPIs offer a novel approach to support cardiac rehabilitation and chronic disease management.
Abstract

Keywords:
heart failurehypertensionmobile phonemyocardial ischemiatelemedicinetext messaging

More Related Videos

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.1K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.9K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
140
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
780
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
203
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
160
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
169
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
651